Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InventivaIVEVF 40 EV-to-OCF is -7.83 as of Aug. 10, 2026. GuruFocus rates IVEVF with a GF Score™ of 40/100 and a GF Value™ of $0.27 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,405 Biotechnology companies, Inventiva ranks better than 64.98% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Inventiva's Enterprise Value is $954.46 Mil.
Inventiva's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-121.87 Mil. Therefore, Inventiva's EV-to-OCF for today is -7.83.
The historical rank and industry rank for Inventiva's EV-to-OCF or its related term are showing as below:
IVEVF'
s EV-to-OCF Range Over the Past 10 Years
Min: -13.13 Med: -2.44 Max: 0.68
Current: -7.9
During the past 13 years, the highest EV-to-OCF of Inventiva was 0.68. The lowest was -13.13. And the median was -2.44.
IVEVF's EV-to-OCF is ranked better than 64.98% of 1405
companies
in the Biotechnology industry
Industry Median: -3.45
vs IVEVF: -7.90
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Inventiva's share price for today is $3.59.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Inventiva's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.950.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Inventiva EV-to-OCF Related Terms
Inventiva EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Inventiva's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Inventiva's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inventiva EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inventiva's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Inventiva's EV-to-OCF falls into.
Inventiva's current Enterprise Value is $954.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Inventiva's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-121.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inventiva (IVEVF) has a EV-to-OCF of -7.83 as of Aug. 10, 2026. According to the industry distribution chart, Inventiva ranks #492 out of 1405 companies in the Biotechnology industry, placing it in the top 35%.
Is Inventiva's EV-to-OCF too high?
Inventiva's current EV-to-OCF is -7.83. Based on the distribution chart, Inventiva ranks #492 out of 1405 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Inventiva has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inventiva's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inventiva ranks #492 out of 1405 companies for EV-to-OCF. This puts Inventiva in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Inventiva's current EV-to-OCF is -7.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inventiva stock overvalued right now?
Based on GuruFocus' analysis, Inventiva (IVEVF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $3.59 — trading 1229.6% above its estimated fair value. The current EV-to-OCF is -7.83. Inventiva's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Inventiva (IVEVF), the current EV-to-OCF is -7.83 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inventiva (IVEVF) Overvalued in 2026?
Based on GuruFocus' analysis, Inventiva stock appears to be overvalued.
The current stock price of $3.59 is trading 1229.6% above its estimated GF Value™ of $0.27.
GuruFocus considers Inventiva to be Significantly Overvalued.
Key valuation signals for IVEVF:
EV-to-OCF: -7.83
GF Value™: $0.27 vs. price of $3.59 (1229.6% above fair value)
No single metric tells the full story. See the IVEVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
40GF Score
Get the complete analysis for IVEVF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVEVF has been successfully added to your 
